Novavax Inc said on Thursday it would require six months to produce a COVID-19 vaccine designed to match whichever coronavirus variants are circulating for an annual immunization program each fall season in the United States.
The company suggested that the U.S. Food and Drug Administration select the prevalent variant of coronavirus in the first quarter each year, similar to the model employed to choose the composition for annual flu shots.
The FDA in documents released on Monday proposed June for deciding on an annual COVID shot's make-up.
Novavax's protein-based vaccine requires manufacturing changes that take longer to implement than the messenger RNA vaccines produced by Pfizer Inc/BioNTech SE and Moderna Inc. It took those companies about three months to produce the currently available boosters updated to target newer Omicron subvariants.
"We recognize the tension between selecting a strain as late as possible to increase the likelihood of recommending a matching strain versus providing adequate time to ensure vaccine availability," Novavax Chief Medical Officer Filip Dubovsky said during a presentation for the FDA's vaccine advisory panel.
The FDA is seeking recommendations from its panel of external experts on adopting an annual COVID shot for the United States and the process for choosing the vaccine's targets each year.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Rapido offers free rides to voters to polling stations on May 13 in Hyderabad, 3 other cities
May 6, 2024 5:49 PM
Lok Sabha elections 2024: Seats to date, all you need to know about third phase of voting
May 6, 2024 4:49 PM
Concerns on low voter turnout a "myth"; absolute number of voters correct way to analyse: Report
May 6, 2024 2:57 PM
Haryana Lok Sabha elections 2024: A look at JJP candidates
May 6, 2024 2:26 PM